Clinical Trial

SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

Name: SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection — clinical trial record (NCT07096882)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).

Trial Details

NCT Number	NCT07096882
Lead Sponsor	Cytocraft Biopharmaceutical Co., Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	22 participants
Start Date	2025-07-26
Primary Completion	2027-06-26 (estimated)
Study Completion	2029-06-26 (estimated)
Updated on ClinicalTrials.gov	2025-07-31